Paper Details

  1. Home
  2. Paper Details

[Chemo-(hormonal)-therapy of advanced ovarian neoplasms in FIGO stages III and IV. Prospective SAKK-study 20/71].

Author: BrunnerK W, Castaño-AlmendralA, LeiD, MartzG, MelchertF, ObrechtP, RhombergW, SennH J

Clinical TrialA clinical trial is a planned study conducted on humans to evaluate the efficacy and safety of pharmaceuticals, medical devices, and treatment methods. It aims to explore the possibilities of new treatments and improve the health of patients.
English AbstractA summary of a research paper/publication written in English for a wider audience.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

Cyclophosphamide (CYT) combined with either medroxyprogesterone acetate (GEST) or 5-fluorouracil (FU) showed a trend towards higher remission rates in patients with advanced ovarian cancer compared to CYT alone. Remission duration and survival were slightly longer in patients receiving combination therapies, but no treatment regimen was superior.
Paper Details　
Original Abstract of the Article :
From 1971 to 1974 89 patients with advanced ovarian cancer (FIGO-stage III-IV), admitted to seven centers of the Swiss Group for Clinical Cancer Research (SAKK), were randomly allocated to three different treatment schedules: cyclophosphamide (CYT) alone or CYT in combination with either medroxyprog...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://pubmed.ncbi.nlm.nih.gov/7423163

データ提供：米国国立医学図書館（NLM）

Treating Advanced Ovarian Cancer: A Clinical Trial Perspective

Ovarian cancer is a complex and challenging disease, particularly when it reaches advanced stages. This study investigates the effectiveness of different chemotherapy regimens in treating advanced ovarian cancer, comparing the outcomes of cyclophosphamide alone or combined with medroxyprogesterone acetate or 5-fluorouracil. It's like trying different strategies to navigate a treacherous desert, searching for the most effective path to overcome a formidable obstacle.

The study found that while none of the regimens were significantly superior in terms of overall remission rate or survival, there was a trend towards higher remission rates with cyclophosphamide combined with 5-fluorouracil. This highlights the importance of ongoing research to develop more effective treatments for advanced ovarian cancer, like searching for a new and more reliable source of water in a parched desert.

Battling Ovarian Cancer: A Journey of Hope

This study provides insights into the treatment landscape for advanced ovarian cancer, highlighting the need for continued research to improve therapeutic options and enhance survival rates. It's like a persistent camel searching for a hidden oasis, offering a glimmer of hope in the face of a challenging journey.

Dr. Camel's Conclusion

This study sheds light on the complexities of treating advanced ovarian cancer, highlighting the need for continued research to develop more effective and individualized treatments. It emphasizes the importance of collaborative efforts and a multidisciplinary approach to combat this challenging disease, striving to create a brighter future for patients facing this diagnosis.

Date :
  1. Date Completed 1980-12-16
  2. Date Revised 2013-11-21
Further Info :

Pubmed ID

7423163

DOI: Digital Object Identifier

7423163

SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.